In August 2018 it was announced that PaxVax had been acquired by Emergent BioSolutions from its majority owner Cerberus Capital Management in an all cash deal. With facilities also in San Diego and Switzerland, PaxVax Inc engages in developing, commercializing, and distributing candidate oral preventative vaccines against various infectious diseases. PaxVax has developed a proprietary oral vaccine technology based on a common virus called adenovirus. The technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and administration by medical personnel. Established in response to the global threat of the H5N1 pandemic, founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Capabilities and technologies have expanded to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Product pipeline includes Typhoid In Market - Live Bacterial; Cholera -Phase III Completed; Hepatis A - Technology Transfer Ongoing ; Virosome - H5N1; Avian Influenza - Phase I Completed Live AD 4/7 Oral Vector ; HIV - Phase I Ongoing; Anthrax - Phase I Ongoing; denovirus 4/7 -- Preclinical
